About this Journal Submit a Manuscript Table of Contents
Advances in Pharmacological Sciences
Volume 2013 (2013), Article ID 194389, 5 pages
http://dx.doi.org/10.1155/2013/194389
Clinical Study

Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population

1Department of Pharmacy, Jewish Hospital, 200 Abraham Flexner Way, Louisville, KY 40202, USA
2Department of Pharmacy, Johnson City Medical Center, 400 North State of Franklin Road, Johnson City, TN 37604, USA
3Department of Statistics, West Virginia University, P.O. Box 9190, Morgantown, WV 26506, USA
4Department of Pharmacy, West Virginia University Healthcare, 1 Medical Center Drive, Morgantown, WV 26506, USA
5Osborn Hematopoietic Malignancy and Transplantation Program, Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV 26506, USA

Received 23 April 2013; Revised 25 July 2013; Accepted 25 July 2013

Academic Editor: Karim A. Alkadhi

Copyright © 2013 Ashley L. Ross et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. The World Health Organization, “Obesity Fact Sheet,” March 2013, http://www.who.int/topics/obesity/en/.
  2. Centers for Disease Control and Prevention, “Adult Obesity Facts,” March 2013, http://www.cdc.gov/obesity/data/adult.html.
  3. M. P. Pai and D. T. Bearden, “Antimicrobial dosing considerations in obese adult patients: insights from the society of infectious diseases pharmacists,” Pharmacotherapy, vol. 27, no. 8, pp. 1081–1091, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Newman, M. H. Scheetz, O. A. Adeyemi et al., “Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual,” Annals of Pharmacotherapy, vol. 41, no. 10, pp. 1734–1739, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. B. Lee, S. Winstead, and A. M. Cook, “Pharmacokinetic alterations in obesity,” Orthopedics, vol. 29, no. 11, pp. 984–988, 2006. View at Scopus
  6. G. Cheymol, “Clinical pharmacokinetics of drugs in obesity—an update,” Clinical Pharmacokinetics, vol. 25, no. 2, pp. 103–114, 1993. View at Scopus
  7. S. Viriyayudhakorn, S. Thitiarchakul, S. Nachaisit, P. C. Ho, and S. Wanwimolruk, “Pharmacokinetics of quinine in obesity,” Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 94, no. 4, pp. 425–428, 2000. View at Scopus
  8. G. Cheymol, “Effects of obesity on pharmacokinetics: implications for drug therapy,” Clinical Pharmacokinetics, vol. 39, no. 3, pp. 215–231, 2000. View at Scopus
  9. M. J. Lind, J. M. Margison, T. Cerny, N. Thatcher, and P. M. Wilkinson, “Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution,” Cancer Chemotherapy and Pharmacology, vol. 25, no. 2, pp. 139–142, 1989. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Lotia and M. C. Bellamy, “Anaesthesia and morbid obesity,” Continuing Education in Anaesthesia, Critical Care and Pain, vol. 8, no. 5, pp. 151–156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. R. A. Blouin, L. A. Bauer, and D. D. Miller, “Vancomycin pharmacokinetics in normal and morbidly obese subjects,” Antimicrobial Agents and Chemotherapy, vol. 21, no. 4, pp. 575–580, 1982. View at Scopus
  12. I. Sketris, T. Lesar, D. E. Zaske, and R. J. Cipolle, “Effect of obesity on gentamicin pharmacokinetics,” Journal of Clinical Pharmacology, vol. 21, no. 7, pp. 288–293, 1981. View at Scopus
  13. D. T. Bearden and K. A. Rodvold, “Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics,” Clinical Pharmacokinetics, vol. 38, no. 5, pp. 415–426, 2000. View at Scopus
  14. B. L. Erstad, “Dosing of medications in morbidly obese patients in the intensive care unit setting,” Intensive Care Medicine, vol. 30, no. 1, pp. 18–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. S. N. Schwartz, G. J. Pazin, and J. A. Lyon, “A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects,” Journal of Infectious Diseases, vol. 138, no. 4, pp. 499–505, 1978. View at Scopus
  16. R. A. Blouin and G. W. Warren, “Pharmacokinetic considerations in obesity,” Journal of Pharmaceutical Sciences, vol. 88, no. 1, pp. 1–7, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Wurtz, G. Itokazu, and K. Rodvold, “Antimicrobial dosing in obese patients,” Clinical Infectious Diseases, vol. 25, no. 1, pp. 112–118, 1997. View at Scopus
  18. D. J. Rea, J. K. Heimbach, J. P. Grande et al., “Glomerular volume and renal histology in obese and non-obese living kidney donors,” Kidney International, vol. 70, no. 9, pp. 1636–1641, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Bosma, J. A. Krikken, J. J. Homan van der Heide, P. E. De Jong, and G. J. Navis, “Obesity and renal hemodynamics,” Contributions to Nephrology, vol. 151, pp. 184–202, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. L. A. Bauer, W. A. Drew Edwards, E. Patchen Dellinger, and D. A. Simonowitz, “Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients,” European Journal of Clinical Pharmacology, vol. 24, no. 5, pp. 643–647, 1983. View at Scopus
  21. A. M. Traynor, A. N. Nafziger, and J. S. Bertino Jr., “Aminoglycoside dosing weight correction factors for patients of various body sizes,” Antimicrobial Agents and Chemotherapy, vol. 39, no. 2, pp. 545–548, 1995. View at Scopus
  22. M. P. Pai, A. N. Nafziger, and J. S. Bertino Jr., “Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 9, pp. 4006–4011, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Vincent, N. El-Khoury, E. Rondeau, and A. A. El Solh, “Renal function in critically ill, morbidly obese patients,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 12, pp. 1332–1333, 2004. View at Scopus
  24. S. A. Spinler, “Predictive performance of ten equations for estimating creatinine clearance in cardiac patients,” Annals of Pharmacotherapy, vol. 32, no. 12, pp. 1275–1283, 1998. View at Publisher · View at Google Scholar · View at Scopus
  25. D. E. Salazar and G. B. Corcoran, “Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass,” American Journal of Medicine, vol. 84, no. 6, pp. 1053–1060, 1988. View at Scopus
  26. R. E. Dionne, L. A. Bauer, G. A. Gibson, W. O. Griffen Jr., and R. A. Blouin, “Estimating creatinine clearance in morbidity obese patients,” American Journal of Hospital Pharmacy, vol. 38, no. 6, pp. 841–844, 1981. View at Scopus
  27. D. P. Nicolau, C. D. Freeman, P. P. Belliveau, C. H. Nightingale, J. W. Ross, and R. Quintiliani, “Experience with a once-daily aminoglycoside program administered to 2,184 adult patients,” Antimicrobial Agents and Chemotherapy, vol. 39, no. 3, pp. 650–655, 1995. View at Scopus
  28. D. N. Gilbert, B. L. Lee, R. J. Dworkin et al., “A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate,” American Journal of Medicine, vol. 105, no. 3, pp. 182–191, 1998. View at Publisher · View at Google Scholar · View at Scopus